Benapenem PK Phase Ib Multiple-dose Study

Health, Subjective Clinical Trial

Official title:

Single-dose Pharmacokinetic, Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem for Injection in Phase I Clinical Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03578588
• Other study ID #: 5081-CPK-1002
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2015
• Est. completion date: January 13, 2016

Study information

• Verified date: May 2018
• Source: Sihuan Pharmaceutical Holdings Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single-center, randomized, open-label, three-period and three-crossover trial design is adopted in the single-dose pharmacokinetic study. 12adult volunteers, are assigned to 3 groups, B1（250mg), B2 (500mg), and B3 (1000mg). Each group of subjects receive single-dose test drug at different dosages in each period.

The tolerability and pharmacokinetic studies are performed simultaneously. Two doses, 250 mg and 500 mg, are proposed for multiple-dose tolerability and pharmacokinetic studies. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. Each subject receives only one dose, intravenous drip, once daily, for 7 consecutive days

Description:

A single-center, randomized, open-label, three-period and three-crossover trial design is adopted in the single-dose pharmacokinetic study. Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period.

A single-center, randomized, open- label, and dose escalation trial design is used in the multiple-dose tolerability and pharmacokinetic studies. The tolerability and pharmacokinetic studies are performed simultaneously. Two doses, 250 mg and 500 mg, are proposed for multiple-dose tolerability and pharmacokinetic studies. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed. Each subject receives only one dose, intravenous drip, once daily, for 7 consecutive days

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 13, 2016
• Est. primary completion date: January 13, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or female healthy subjects, aged 18 ~ 45;

• Body weight = 50 kg and body mass index 19.0 ~ 24.0 kg/m2;

• Prior to the test, physical examination, blood routine, urine routine, liver and kidney functions, and related examinations normal, or mild abnormalities in indicators while without clinical significance as indicated by the investigator

• Normal or mild abnormalities without clinical significance in the standard 12-lead ECG;

• Signing informed consent form

Exclusion Criteria:

• Regular smoking, alcohol abuse, and drug abuse;

• Use of drugs with known damage to an organ within three months;

• History of specific allergies, or history of drug allergy, especially those allergic to lactams and excipients of test drug;

• Febrile illnesses within three days before the screening;

• Patients with mental illness or psychotic disorder in the past;

• Past mental and nervous system diseases (epilepsy, stroke, cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers, gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory, hematological, or endocrine system, etc.) diseases or medical history.

• Taking any medication, including traditional Chinese medicine;

• Having taken any medication that may affect test results within two weeks before the screening, such as antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics, anticoagulants, central nervous system depressants, and any drug that may affect the drug absorption;

• Having participated in other investigational drug trial in the preceding three months;

• Blood donation for 360 ml or more within three months before the screening;

• Heart rate<50 bpm or >100 bpm;

• Systolic blood pressure < 90 mmHg or = 140 mmHg, diastolic blood pressure = 90 mmHg or < 60 mmHg;

• Women who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable contraception, or who have a positive result in serum pregnancy test;

• Women who are planning to become pregnant within 6 months, or male subjects who are planning to make his spouse pregnant within 6 months;

• HBsAg, HCV antibody, HIV antibody, and Treponema Pallidum antibody positive;

• Urine drug-of-abuse testing positive;

• Any other factor that makes the subject not suitable for the trial as indicated by the investigator.

Related Conditions & MeSH terms

• Health, Subjective

Intervention

Drug:
• Banapenem
Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sihuan Pharmaceutical Holdings Group Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC(0-24) of Benapenem	AUC(0-24) is the area under the curve from time 0 to 24 hours	Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24,36,48 hours after Dosing
Primary	Maximum observed plasma concentration (Cmax) of Benapenem	Maximum observed plasma concentration (Cmax) of following in healthy subjects	Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24,36,48 hours after Dosing
Primary	Time to maximum observed plasma concentration (tmax) of Benapenem	Time to maximum observed plasma concentration (tmax)	Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24,36,48 hours after Dosing
Primary	Time to elimination half-life (t1/2) of Benapenem	Time to elimination half-life (t1/2)	Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24,36,48 hours after Dosing
Secondary	Number of subjects with clinically significant findings in vital signs	Vitals signs such as systolic and diastolic blood pressure, heart rate, and pulse rate will be measured in a semi-supine position after 5 minutes of rest	Screening and Day1, Day 2, Day4 after dosing
Secondary	Number of subjects with clinically significant findings in laboratory parameters	Hematology and Clinical Chemistry and Urine routine abnormalities will be monitored	Screening and Day1, Day 2, Day4 after dosing
Secondary	Number of subjects with adverse events and serious adverse events		Screening and Day1, Day 2, Day4 after dosing
Secondary	Number of subjects with clinically significant 12-lead ECGs	Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals.	Screening and Day1, Day 2, Day4 after dosing